Skip to main content

Table 1 Summary of the colon cancer-associated DLC1-START domain mutations. TCGA colon cancer associated DLC1 START domain mutations and biological properties analyzed in this study

From: The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1

DLC1 mutation Biological inhibition relative to DLC1 WT RhoGAP activity relative to DLC1 WT Caveolin-1 binding PLCD1 binding PS binding Sensitivity to PS changes
S912L reduced similar deficient deficient normal normal
L930P reduced similar deficient deficient normal normal
R947C reduced similar deficient deficient deficient deficient
E966K reduced similar deficient deficient deficient not assayed
C1005F reduced similar normal normal deficient not assayed
A1017T reduced similar normal normal deficient not assayed
C1036S reduced similar normal normal deficient deficient